NOVEL FOOD and PARNUTS Approval Granted for NKO(R) Opens the 2nd Largest Nutraceutical Market for Neptune

Neptune Technologies &
Bioressources Inc. ("Neptune") (NASDAQ.NEPT -  TSX.V.NTB) is pleased
to announce today that the European Food Safety  Association (EFSA)
has approved Neptune Krill Oil (NKO(R)) as a NOVEL FOOD  and PARNUTS
for commercialization in the European Union.

NKO(R) has successfully passed rigorous regulatory review and
scrutiny  by all member states of the European Union (EU), which
approved NKO(R) as a  NOVEL FOOD and PARNUTS allowing its immediate
commercialization at a  clinically proven effective daily dose in all
27 European countries.

<<
    - NOVEL FOOD opens the European market to NKO(R) for:
    - Dietary Supplements
    - Functional Foods
    - PARNUTS approval allows the commercialization of NKO(R) as:
    - Diet Meal Replacements
    - Dietary Foods for Special Medical Purposes >>

"NKO(R)'s strong clinically proven benefits for cardiovascular
health  will now lead Neptune's further expansion in the European
omega-3 market,  which is currently dominated by cardiovascular
health applications with 80%  of all omega-3 fatty acids targeting
heart benefits," stated Dr. Toni  Rinow, Corporate Development and
Investor Relations of Neptune. "According  to market studies, the EU
market is growing annually by 24 % and is expected  to be worth
CDN$1.6 billion by 2014(1)," she added.

"According to EFSA regulations, functional food and dietary
supplements can only be commercialized at the daily dose established
as safe, which is not always necessarily the effective dose.
Fortunately, the daily dose accepted by EFSA as safe for NKO(R) is
also the one proven to be effective in all clinical studies with
NKO(R)," stated Dr. Tina Sampalis, Chief Scientific Officer of
Neptune. "This opens the door for NKO(R) to gain a leadership
position in both dietary supplements and functional food markets,
achieving targets unmet by other omega-3 products and krill
competition," she added.

"Moreover, the NKO(R) PARNUTS approval, which allows the
commercialization of NKO(R) for the dietary management of specific
diseases, is expected to lead Neptune and its subsidiaries to major
pharmaceutical opportunities," she concluded.

Neptune has already built substantial marketing visibility and
recognition in Europe through its longstanding annual presence at
Vitafoods International, the Global Nutraceutical Event, in Geneva,
Switzerland, and Health and Food Ingredients in Paris, France. Based
on these continuing marketing efforts, the proprietary status of its
ingredients and the Novel Food approval, Neptune expects to
accelerate market penetration and increase its market share of the
omega-3 health ingredient market.

(1) Frost & Sullivan's European Analysis 2008

About Neptune Technologies & Bioressources Inc.

Neptune researches and develops proprietary bioactive ingredients
and products for nutraceutical and pharmaceutical applications and is
carrying out clinical research to show the therapeutic benefits of
its products in various medical indications. The Company patents and
protects its innovations and is continuously expanding its
intellectual property portfolio. Neptune has already obtained many
regulatory approvals allowing commercialization of its products in
various geographic markets and has filed for and is expecting
additional approvals. The Company expects to launch its first
functional food product in early 2009 with its partners Marine Life
Science and Weider Global Nutrition.

NASDAQ does not accept responsibility for the adequacy or
accuracy of this press release. Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the policies
of the TSX Venture Exchange) accepts responsibility for the adequacy
or accuracy of this release.

Statements in this press release that are not statements of
historical or current fact, including statments relating to the
Company's expectation regarding the future performance and
marketability of its products, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the actual
results of the Company to be materially different from historical
results or from any future results expressed or implied by such
forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are urged
to consider statements labeled with the terms "believes," "belief,"
"expects," "intends," "anticipates,"should," "will," or "plans" to be
uncertain and forward-looking. The forward-looking statements
contained herein are also subject generally to other risks and
uncertainties that are described from time to time in the Company's
reports filed with the Securities and Exchange Commission and the
Canadian securities commissions.

    For further information:
    Toni Rinow, Ph.D., MBA Corporate Development & Investor Relations,
    Neptune Technologies & Bioressources Inc.,
    +1-450-687-2262,
     t.rinow@neptunebiotech.com,
    http://www.neptunebiotech.com;

Contact:

For further information: Toni Rinow, Ph.D., MBA Corporate Development
& Investor Relations, Neptune Technologies & Bioressources Inc.,
+1-450-687-2262, t.rinow@neptunebiotech.com

NOVEL FOOD and PARNUTS Approval Granted for NKO(R) Opens the 2nd Largest Nutraceutical Market for Neptune

Enterprises

Économie